Celldex Therapeutics CLDX Business Segments — Personnel Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept cldx:PersonnelExpenses.
The official record: Celldex Therapeutics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's business segments — personnel expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's business segments — personnel expenses?
- Celldex Therapeutics (CLDX) reported business segments — personnel expenses of $14.3M in Q4 2025.
- How has Celldex Therapeutics's business segments — personnel expenses changed year-over-year?
- Celldex Therapeutics's business segments — personnel expenses increased by 10.2% year-over-year, from $12.98M to $14.3M.
- What is the long-term trend for Celldex Therapeutics's business segments — personnel expenses?
- Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — personnel expenses has grown at a 20.5% compound annual growth rate (CAGR), from $32.67M to $57.2M.
- What does business segments — personnel expenses mean?
- This metric reflects the total payroll, bonuses, and stock-based compensation for employees assigned to the company's primary business segment. It represents the core investment in the human resources necessary to execute the company's strategic research and development roadmap. Changes in this metric often correlate with shifts in the company's headcount and organizational scaling.